摘要
目的探讨密集化疗联合靶向治疗治疗转移性乳腺癌的疗效及安全性。方法选择68例人类表皮生长因子受体2(HER2)阳性转移性乳腺癌患者作为研究对象,根据治疗方案的不同将患者分为A组(n=30)和B组(n=38)。A组患者接受表柔比星+环磷酰胺,序贯紫杉醇的剂量密集化疗方案,B组患者在此基础上联合采用曲妥珠单抗靶向治疗。出院后,对两组患者进行为期3年的随访。比较两组患者的不良反应发生率、临床疗效、生活质量及3年总生存率。HER2阳性转移性乳腺癌患者临床疗效的影响因素采用Logistic回归分析。结果 A组患者的不良反应总发生率为40.00%,B组患者的不良反应总发生率为50.00%,差异无统计学意义(P﹥0.05)。B组患者总缓解率、生活质量核心量表(QLQ-C30)评分均明显优于A组患者(P﹤0.01)。B组和A组患者的3年生存率分别为60.0%和30.6%,B组患者的生存情况优于A组(P﹤0.05)。Logistic回归分析显示,转移器官数量是转移性乳腺癌患者临床疗效的影响因素。结论密集化疗联合靶向治疗可提高转移性乳腺癌患者的肿瘤缓解率,延长患者的生存时间,提高患者的生活质量,且安全性较好。
Objective To explore the safety and efficacy of intensive chemotherapy combined with targeted therapy in patients with metastatic breast carcinoma.Method 66 patients with human epidermal growth factor receptor 2(HER2)positive metastatic breast carcinoma were included in the study and were divided into two groups(A and B)according to different treatment regimens,with 30 patients in group A and 38 patients in group B,respectively.Group A received intensive chemotherapy of cyclophosphamide+epirubicin and sequential paclitaxel regimen,while group B was given targeted therapy bevacizumab on the basis of the regimen administered in group A.All patients were followed up after discharge for 3 years.The incidence of adverse reactions,clinical efficacy,quality of life,and overall survival in 3 years of the two groups were collected and compared.In addition,factors influencing the clinical efficacy in patients with HER2 positive metastatic breast carcinoma were assessed through Logistic regression analysis.Result The overall survival incidence of adverse reactions in group A was 40.00%,and that in group B was 50.00%,with no statistically significant difference observed between the two groups(P >0.05).The overall response rate,and quality of life questionnairecore 30(QLQ-C30)score,were better than that in group A(P<0.01).The 3-year survival rates of patients in group A and group B were 60.0%and 30.6%,respectively,the survival rate of patients in group B was better than that in group A(P<0.05).Logistic regression analysis showed that the number of metastatic organs was key factor influencing the clinical efficacy of metastatic breast carcinoma.Conclusion Intensive chemotherapy combined with targeted therapy can improve the remission rate,survival rate and quality of life in patients with metastatic breast carcinoma,with fairly acceptable safety.
作者
朱志远
陈平
赵霞
马靓
钱琦
ZHU Zhiyuan;CHEN Ping;ZHAO Xia;MALiang;QIAN Qi(Department of Medical Oncology,Yancheng City No.1 People’s Hospital,Yancheng 224000,Jiangsu,China)
出处
《癌症进展》
2019年第2期165-168,共4页
Oncology Progress
关键词
转移性乳腺癌
分子靶向治疗
密集化疗
不良反应
临床疗效
metastatic breast carcinoma
molecular targeted therapy
intensive chemotherapy
adverse reactions
clinical efficacy
作者简介
通信作者:朱志远,邮箱:zhl1988444@163.com.
